Citi Starts Dicerna Pharmaceuticals (DRNA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Dicerna Pharmaceuticals (DRNA) PT Lowered to $20 at H.C. Wainwright on Dilution
September 13, 2018 7:16 AM EDTH.C. Wainwright analyst Ed Arce lowered the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $20.00 (from $21.00) while maintaining a Buy rating, citing dilution.
Arce commented, "Last week, as we expected, Dicerna announced positive initial 6-week data (Day 43) in which most (5 of 8) assessed PH patients in Group B of... More
